Literature DB >> 24749731

Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation.

Karl Haslam1, Stephen E Langabeer, Karen Molloy, Mary F McMullin, Eibhlin Conneally.   

Abstract

Entities:  

Keywords:  CALR mutations; allogeneic stem cell transplantation; myelofibrosis

Mesh：

Substances：

Year:  2014        PMID： 24749731     DOI： 10.1111/bjh.12904

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  11 in total

Review 1.  What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors:  Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

2.  Impact of molecular residual disease post allografting in myelofibrosis patients.

Authors:  C Wolschke; A Badbaran; T Zabelina; M Christopeit; F Ayuk; I Triviai; A Zander; H Alchalby; U Bacher; B Fehse; N Kröger
Journal:  Bone Marrow Transplant       Date:  2017-07-17       Impact factor: 5.483

3.  Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR.

Authors:  Michael Zinke; Vanasa Nageswaran; Richard Reinhardt; Thomas Burmeister
Journal:  Mol Diagn Ther       Date:  2015-10       Impact factor: 4.074

4.  Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation.

Authors:  A Badbaran; B Fehse; M Christopeit; T Aranyossy; F A Ayuk; C Wolschke; N Kröger
Journal:  Bone Marrow Transplant       Date:  2016-02-15       Impact factor: 5.483

Review 5.  Monitoring residual disease in the ph-negative myeloproliferative neoplasms post-allogeneic stem cell transplantation: more mutations and more methodologies.

Authors:  Stephen E Langabeer; Karl Haslam; Eibhlin Conneally
Journal:  Front Oncol       Date:  2014-08-08       Impact factor: 6.244

6.  Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia.

Authors:  Stephen E Langabeer; Karl Haslam; David O'Brien; Johanna Kelly; Claire Andrews; Ciara Ryan; Richard Flavin; Patrick J Hayden; Christopher L Bacon
Journal:  Case Rep Hematol       Date:  2016-01-21

7.  Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.

Authors:  Lasse Kjær; Sabrina Cordua; Morten O Holmström; Mads Thomassen; Torben A Kruse; Niels Pallisgaard; Thomas S Larsen; Karin de Stricker; Vibe Skov; Hans C Hasselbalch
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

Review 8.  Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches.

Authors:  Karl Haslam; Stephen E Langabeer
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

9.  Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation.

Authors:  Stephen E Langabeer; James Nolan; Karl Haslam; Lindsey Clarke; Richard Flavin; Eibhlin Conneally
Journal:  Case Rep Hematol       Date:  2015-08-09

Review 10.  Allogeneic hematopoietic stem-cell transplantation for myelofibrosis.

Authors:  Lining Zhang; Fan Yang; Sizhou Feng
Journal:  Ther Adv Hematol       Date:  2020-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.